Bio-Light Israeli (BLGTY) 5.1300 $BLGTY BioLight

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 8:53 AM

Bio-Light Israeli (BLGTY) 5.1300 $BLGTY

BioLight Announces Closing of Upsized US$6.6 Million Private Placement
PR Newswire - Tue May 12, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that it has completed an upsized private placement as part of the strategic partnership with Rock-One International Holdings Ltd for aggregate gross proceeds of US$6.6 million.

BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.

Week In Review: aTyr Pharma To Raise $86 Million In IPO
ChinaBio Today - at Seeking Alpha - Sun Apr 12, 5:07AM CDT
Deals and Financings aTyr Pharma (Pending: LIFE ), a San Diego-Hong Kong clinical stage biotherapeutics company, filed to conduct an $86 million IPO on the Nasdaq exchange (see story ). The company develops Physiocrine-based therapeutics to...
LIFE: 20.13 (-0.45), CYTX: 0.66 (-0.02)

BioLight: Developments Are Chugging Along Smoothly
Anita Dushyanth - at Seeking Alpha - Wed Apr 08, 11:11AM CDT

BioLight Announces First IOPtiMate(TM) System Sale in Poland
PR Newswire - Mon Dec 01, 8:00AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system to a medical center located in Poland following a successful product trial.

Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman"

, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target.

BioLight to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Wed Oct 22, 9:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.

BioLight to Present its IOPtiMate(TM) System at the Ophthalmology Innovation Summit @ the American Academy of Ophthalmology 2014
PR Newswire - Mon Oct 13, 8:00AM CDT
BioLight Life Sciences Investments Ltd.(TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.

Merriman Capital Announces Sponsorship of BioLight Life Sciences Investments Ltd. on OTCQX
Thomson Reuters ONE - Tue Sep 23, 8:00AM CDT
SAN FRANCISCO - September 23, 2014 - Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it will serve as the Principal American Liaison (PAL) for BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) ("BioLight"

as it continues trading on OTCQX(R).

BioLight Announces First IOPtiMate(TM) System Sale in Hong Kong
PR Newswire - Wed Sep 10, 7:49AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system in Hong Kong.

BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform
PR Newswire - Wed Jul 02, 8:23AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT) (OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces the U.S. Patent and Trademark Office has issued patent number 8,765,166 covering the device that is inserted into the eye to treat an ocular condition that contains an active agent of a free acid salt form of a prostaglandin with a low elution rate profile that is contained in the long-term controlled-release insert platform. The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company's controlled-release latanoprost insert currently in a Phase 1/2a clinical study in the U.S. for the treatment of glaucoma.

BioLight Reports Successful Interim Results from Bladder Cancer Clinical Study
PR Newswire - Tue Jul 01, 4:23PM CDT
BioLight Life Sciences Investments Ltd. (OTC: BLGTY)(TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. As a result, Micromedic will continue the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This study is being conducted at seven medical centers and is expected to be completed in the fourth quarter of 2014.

First Patient Enrolled in FDA Phase 1/2a Clinical Trial With BioLight's Controlled-Release Latanoprost Insert for the Treatment of Glaucoma
PR Newswire - Mon Jun 30, 8:00AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D®, the company's controlled-release latanoprost insert for the treatment of glaucoma.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...